Screener
Gyre Therapeutics, Inc. GYRE Gyre — Transaction Costs
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept gyre:TransactionCosts.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Gyre Pharmaceuticals | Gyre | Total |
|---|---|---|---|
| Research and development | 9,697 | 4,603 | 14,300 |
| Research and development - related parties | 4,836 | — | 4,836 |
| General and administrative | 4,268 | 3,594 | 7,862 |
| Transaction costs | — | 502 | 502 |
| Total segment operating expenses | 34,764 | 8,699 | 43,463 |
| Loss from segment operations | (5,667) | (8,691) | (14,358) |
| Other segment (loss) income, net: | |||
| Interest income | 252 | 488 | 740 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre — transaction costs?
- Gyre Therapeutics, Inc. (GYRE) reported gyre — transaction costs of $502K in Q2 2026.
- What does gyre — transaction costs mean?
- These are the non-recurring expenses directly associated with executing specific business transactions, such as mergers, acquisitions, or divestitures. These costs are typically excluded from core operating performance to provide a clearer view of ongoing business health. Tracking these helps investors understand the impact of corporate development activities on the bottom line.
Ask your AI about Gyre Therapeutics, Inc.'s gyre — transaction costs.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude